What question did this study set out to answer?

To determine whether intratracheal treatment with the lipopolysaccharide antagonist E5564 prevents chronic endotoxin-induced airway disease in a murine model.

April 16, 2005AJP Lung Cellular and Molecular Physiology

Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide

View Full Paper

Ask AI

Bookmark

Authors

JSJordan D. SavovDuke Medical Center DBDavid M. BrassApple (Israel)BLBarbara L. LawsonDuke Medical Center

Discussion

Member takes

Implication

Animal study demonstrates that a Toll-like receptor 4 antagonist reduces chronic endotoxin-induced airway inflammation and remodeling in mice, suggesting a therapy for environmental airway disease.

Key Points

To determine whether intratracheal treatment with the lipopolysaccharide antagonist E5564 prevents chronic endotoxin-induced airway disease in a murine model.
Assessed toxicity and airway inhibition duration after administering intratracheal doses of E5564 (10, 50, or 100 μg) in mice.
Treated mice with E5564 (50 μg) or vehicle three times weekly for 5 weeks during daily exposure to aerosolized lipopolysaccharide (4.65 ± 0.30 μg/m³) or saline, followed by a 4-week recovery period.
E5564 significantly reduced methacholine-induced airway hyperreactivity, air space neutrophilia, neutrophil infiltration, and lung lavage interleukin-6 concentrations evaluated 36 hours post-exposure.
Mice receiving E5564 demonstrated less airway collagen deposition compared with vehicle-treated controls after the 4-week recovery phase.

Cite This Study

Savov et al. (2005) studied this question.

synapsesocial.com/papers/6a9e73709b2dbee2f9368d6c https://doi.org/10.1152/ajplung.00014.2005

View Full Paper

Ask AI

Bookmark

Implication

Animal study demonstrates that a Toll-like receptor 4 antagonist reduces chronic endotoxin-induced airway inflammation and remodeling in mice, suggesting a therapy for environmental airway disease.

Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide

Discussion

Member takes

Implication

Key Points

Cite This Study

Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider